Roche posted a solid quarter that came in about CHF100m above expectations, driven by Perjeta and Mircera in the Pharmaceutical division. Both divisions grew 6% CER. Outlook for revenue growth in 2015 is raised to mid-single digit although this should not drive meaningful CS revisions. In conclusion, slightly better than expected figures in Q3 but limited impact on CS numbers to be expected.
For more information, please contact email@example.com